Acorda Therapeutics, Inc. announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson’s disease.
CVT-301 is being studied as a self-administered inhaled levodopa (L-dopa) therapy for the treatment of symptoms of OFF periods in people with Parkinson’s disease following an oral carbidopa / levodopa regimen.
Acorda’s share price shows that the company has outperformed the Zacks classified Medical - Biomedical and Genetics year to date. The stock returned 43.4% compared with industry’s gain of 6.7%.
In fact, both the studies, CVT-301-005 and CVT-301-004E, involved about 700 participants.
In study of CVT-301-005, 271 participants with Parkinson's who did not have a history of asthma or other chronic lung disease received CVT-301 84 mg up to five times daily, along with usual Parkinson’s standard of care. Also, all ongoing participants completed their 36-week visit and 199 participants completed their 52-week visit.
On the contrary, in the other study of CVT-301-004E, the patients either received 84 mg dose of CVT-301 or 60 mg dose of CVT-301. There was no control arm in the study. At the time of this analysis, 70 participants completed their 36-week visit and 49 participants completed their 52-week visit.
Data from both studies will be submitted for presentation at a future medical meeting.
Moving ahead, Acorda plans to file a New Drug Applicatiion (NDA) in the second quarter of 2017 and file a Marketing Authorization Application (MAA) in Europe by the end of 2017 pending further analysis.
In Feb 2017, the company announced positive phase III clinical data on CVT-301 for the treatment of OFF episodes in Parkinson’s disease patients.
Zacks Rank & Stocks to Consider
Acorda currently carries a Zacks Rank #3 (Hold). Some other better-ranked stocks in the health care sector include Heska Corporation , Retrophin, Inc. and Galena Biopharma, Inc. . All the three companies carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates moved up from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 30 days. The company posted a positive earnings surprise in all of the last four quarters, with an average beat of 291.54%. Its share price increased 33.8% year to date.
Retrophin’s loss estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018, over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%.
Galena Biopharma‘s loss estimates narrowed from $2.53 to 58 cents for 2017 and from $1.95 to 73 cents for 2018, over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 53.83%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Image: Bigstock
Acorda Presents Data for Parkinson's Candidate CVT-301
Acorda Therapeutics, Inc. announced results from two ongoing, long-term safety studies of CVT-301 in patients suffering with Parkinson’s disease.
CVT-301 is being studied as a self-administered inhaled levodopa (L-dopa) therapy for the treatment of symptoms of OFF periods in people with Parkinson’s disease following an oral carbidopa / levodopa regimen.
Acorda’s share price shows that the company has outperformed the Zacks classified Medical - Biomedical and Genetics year to date. The stock returned 43.4% compared with industry’s gain of 6.7%.
In fact, both the studies, CVT-301-005 and CVT-301-004E, involved about 700 participants.
In study of CVT-301-005, 271 participants with Parkinson's who did not have a history of asthma or other chronic lung disease received CVT-301 84 mg up to five times daily, along with usual Parkinson’s standard of care. Also, all ongoing participants completed their 36-week visit and 199 participants completed their 52-week visit.
On the contrary, in the other study of CVT-301-004E, the patients either received 84 mg dose of CVT-301 or 60 mg dose of CVT-301. There was no control arm in the study. At the time of this analysis, 70 participants completed their 36-week visit and 49 participants completed their 52-week visit.
Data from both studies will be submitted for presentation at a future medical meeting.
Moving ahead, Acorda plans to file a New Drug Applicatiion (NDA) in the second quarter of 2017 and file a Marketing Authorization Application (MAA) in Europe by the end of 2017 pending further analysis.
In Feb 2017, the company announced positive phase III clinical data on CVT-301 for the treatment of OFF episodes in Parkinson’s disease patients.
Acorda Therapeutics, Inc. Price
Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Acorda currently carries a Zacks Rank #3 (Hold). Some other better-ranked stocks in the health care sector include Heska Corporation , Retrophin, Inc. and Galena Biopharma, Inc. . All the three companies carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates moved up from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 30 days. The company posted a positive earnings surprise in all of the last four quarters, with an average beat of 291.54%. Its share price increased 33.8% year to date.
Retrophin’s loss estimates narrowed from 85 cents to 72 cents for 2017 and from 67 cents to 53 cents for 2018, over the last 30 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 80.55%.
Galena Biopharma‘s loss estimates narrowed from $2.53 to 58 cents for 2017 and from $1.95 to 73 cents for 2018, over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 53.83%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>